Incidental detection of population-based prostate cancer incidence rates through transurethral resection of the prostate

Urologic Oncology

Volumn 7, Issue 5, 2002, Pages 213-219

  Merrill, Ray M ^a   Wiggins, Charles L ^b  

^a BRIGHAM YOUNG UNIVERSITY   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Benign prosastatic hyperplasia; Prostate specific antigen; Prostatectomy; Prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ALGORITHM; ARTICLE; CANCER GRADING; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER STAGING; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; TRANSURETHRAL RESECTION; UNITED STATES; DATA BASE; GROUPS BY AGE; HISTOLOGY; HUMAN TISSUE; INCIDENCE; PROSTATE CANCER;

AGED; BIOPSY, NEEDLE; HUMANS; INCIDENCE; MALE; MASS SCREENING; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REGISTRIES; SEER PROGRAM; SENSITIVITY AND SPECIFICITY; TRANSURETHRAL RESECTION OF PROSTATE; UNITED STATES;

EID: 0036765249     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-1439(02)00193-X     Document Type: Article

References (45)

1. Greenlee R.T., Hill-Harmon M.B., Murray T., Thun M. Cancer statistics, 2001. CA Cancer J Clin. 51:2001;15-36.
2. Ries LAG, Eisner MP, Kosary CL, et al. SEER cancer statistics review, 1973-1998, Section 22 - Prostate Cancer, Table XXII-6, National Cancer Institute, Bethesda, MD. Retrieved from: http://seer.cancer.gov/Publications/CSR1973_1998/ Accessed October 12, 2001.
3. Andrews G.S. Latent carcinoma of the prostate. J Clin Path. 2:1949;197.
4. Edwards C.N., Steinthorsson E., Nicholson D. An autopsy of latent prostatic cancer. Cancer. 6:1953;531.
5. Hirst Jr. AE, Bergman RT. Carcinoma of the prostate in men 80 or more years old. Cancer 1954;7:136.
6. Whitmore Jr. WF. Symposium of hormones and cancer therapy hormone therapy in prostatic cancer. Amer J Med 1956;21:295.
7. Scott Jr R, Mutchnik DL, Laskowski TZ, Schmalhorst WR. Carcinoma of the prostate in elderly men. incidence, growth characteristics and clinical significance J Urol. 101:1969;602.
8. Breslow N., Chan C.W., Dhom G.et al. Latent carcinoma of the prostate at autopsy in seven areas. Int J Cancer. 20:1977;680-688.
9. Carter H.B., Piantadosi S., Isaacs J.T. Clinical evidence for and implications of the multistep development of prostate cancer. J Urol. 143:1990;742-746.
10. Waterbor J.W., Bueschen A.J. Prostate cancer screening (United States). Cancer Causes Control. 6:1995;267-274.
11. Merrill R.M., Feuer E.J., Warren J.L., Schussler N., Stephenson R.A. Role of transurethral resection of the prostate in population-based prostate cancer incidence rates. Am J Epidemiol. 150:1999;848-860.
12. Hankey B.F., Ries L.A., Edwards B.K. The Surveillance, Epidemiology, and End Results Program. a national resource Cancer Epidemiol Biomarkers Prev. 8:1999;1117-1121.
13. Percy C., Van Holten V., Muir C. International classification of diseases for oncology. Second Edition:1990;World Health Organization, Geneva.
14. Shambaugh EM, Weiss MA, Axtell LM. Summary staging guide for the cancer Surveillance, Epidemiology, and End Results (SEER) Program. US Department of Health and Human Services. Public Health Service. National Institutes of Health. NIH Publication No. 81-2313. January 1981.
15. Ries L, Fritz A., editors. The SEER program code manual. Third Edition. Surveillance Program, Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health. Bethesda, MD, 1998.
16. North American Association of Central Cancer Registries. Standards for cancer registries. Volume III. Standards for completeness, quality, analysis, and management of data. September 2000.
17. Utah Hospital Discharge Database. 2000 public-use data file. User's manual version 1, October 2001. Utah Health Data Committee, Office of Health Care Statistics, Utah Department of Health. Retrieved from: http://hlunix.hl.state.ut.us/hda/Reports/PDS2000MAN_I.pdf Accessed March 13, 2002.
18. Hospital and Payor ICD-9-CM. Medicode's 1999 publications and software for coders. Volume 3, page 142.
19. PDQ information on prostate cancer treatment. Retrieved from: http://cancernet.nci.nih.gov/clinpdq/pif/Prostate_cancer_Patient.html Accessed October 13, 2001.
20. Shambaugh EM, Ries LG, Young Jr. JL, Kruse MA. SEER extent of disease - 1988. Codes and coding instructions. 2nd edition. National Cancer Institute. Bethesda, MD, 1999.
21. Kahn H.A., Sempos C.T. Statistical methods in epidemiology. Monographs in epidemiology and biostatistics, Volume 12. 1989;Oxford University Press, New York.
22. U.S. Populations. U.S. Bureau of the Census. Unpublished data. Available at http://seer.cancer.gov/USPops/ Accessed October 12, 2001.
23. The SAS System for Windows. Proprietary Software Release 8.2, Copyright 1999-2001 by SAS Institute Inc., Cary, NC, USA.
24. Chisholm G.D. Handbook on benign prostatic hyperplasia. 1994;Merk & Co., Inc, Whitehouse Station, NJ.
25. Uchida T., Ohori M., Soh S.et al. Factors influencing morbidity in patients undergoing transurethral resection of the prostate. Urology. 53:1999;98-105.
26. Matani Y., Mottrie A.M., Stockle M.et al. Transurethral prostatectomy. a long-term follow-up study of 166 patients over 80 years of age Eur Urol. 30:1996;414-417.
27. Potosky AL, Kessler l, Gridley G, et al. Rise in prostatic cancer incidence associated with increased use of transurethral resection. 1990 J Natl Cancer Inst 82:1624-8.
28. Levy I.G., Gibbons L., Collins J.P.et al. Prostate cancer trends in Canada. rising incidence or increased detection? Can Med Assoc J. 149:1993;617-623.
29. Wasson J.H., Bubolz T.A., Lu-Yao G.L.et al. Transurethral resection of the prostate among medicare beneficiaries. 1984 to 1997. For the patient outcomes research team for prostatic diseases J Urol. 164:2000;1212-1215.
30. Baine W.B., Yu W., Summe J.P., Weis K.A. Epidemiologic trends in the evaluation and treatment of lower urinary tract symptoms in elderly male medicare patients from 1991 to 1995. J Urol. 160:1998;816-820.
31. Xia Z., Roberts R.O., Schottenfeld D., Lieber M.M., Jacobsen S.J. Trends in prostatectomy for benign prostatic hyperplasia among black and white men in the United States. 1980 to 1994 Urology. 53:1999;1154-1159.
32. Gormley G.J., Stoner E., Bruskewitz R.C.et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med. 327:1992;1185-1191.
33. Finasteride Study Group Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate. 22:1993;291-299.
34. Prostate Enlargement. Benign prostatic hyperplasia. Bethesda, MD, National Institutes of Health. 1996 NIH publication no. 91-3012.
35. Clifford G.M., Logie J., Farmer R.D. How do symptoms indicative of BPH progress in real life practice? The UK experience. Eur Urol. 38(Suppl S1):2000;48-53.
36. Andersen M., Dahlstrand C., Hoye K. Double-blind trial of the efficacy and tolerability of doxazosin in the gastrointestinal therapeutic system, doxazosin standard, and placebo in patients with benign prostateic hyperplasia. Eur Urol. 38:2000;400-409.
37. Wilde M.I., Goa K.L. Finasteride. An update of its use in the management of symptomatic benign prostatic hyperplasia. Drugs. 57:1999;557-581.
38. Lynch J.H., Hofner K. Transurethral microwave thermotherapy. Eur Urol. 35:1999;129-137.
39. Legler J.M., Feuer E.J., Potosky A.L., Merrill R.M., Kramer B.S. The role of prostate-specific antigen (PSA) testing patterns in the recent prostate cancer incidence decline in the United States. Cancer Causes Control. 9:1998;519-527.
40. Potosky A.L., Miller B.A., Albertsen P.C.et al. The role of increasing detection in the rising incidence of prostate cancer. JAMA. 273:1995;548-552.
41. Newman Jr AJ, Graham MA, Carlton Jr. CE, et al. Incidental carcinoma of the prostate at the time of transurethral resection. importance of evaluating every chip J Urol. 128:1982;948-950.
42. Sheldon C.A., Williams R.D., Fraley E.E. Incidental carcinoma of the prostate. a review of the literature and critical reappraisal of classification J Urol. 124:1980;626-631.
43. Rohr L.R. Incidental adenocarcinoma in transurethral resections of the prostate. Partial versus complete microscopic examination. Am J Surg Pathol. 11:1987;53-58.
44. Stanford JL, Stephenson RA, Coyle LM, et al. Prostate cancer trends 1973-1995, SEER Program, National Cancer Institute NIH Pub. No. 99-4543. Bethesda, MD, 1999.
45. Harlan L., Brawley O., Pommerenke F., Wali P., Kramer B. Geographic, age, and racial variation in the treatment of local/regional carcinoma of the prostate. J Clin Oncol. 13:1995;93-100.